Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: A case series

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Delsing, Corine E ^a   Gresnigt, Mark S ^a   Leentjens, Jenneke ^a   Preijers, Frank ^a   Frager, Florence A ^b   Kox, Matthijs ^a   Monneret, Guillaume ^b   Venet, Fabienne ^b   Bleeker Rovers, Chantal P ^a   van de Veerdonk, Frank L ^a   Pickkers, Peter ^a   Pachot, Alexandre ^b   Kullberg, Bart J ^a   Netea, Mihai G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Aspergillosis; Candidemia; Immunotherapy; Interferon gamma

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; FLUCONAZOLE; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; ITRACONAZOLE; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN; GAMMA INTERFERON; RECOMBINANT PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ANTIFUNGAL ACTIVITY; ANTIGEN EXPRESSION; ARTICLE; ASPERGILLOSIS; CANDIDEMIA; CANDIDIASIS; CELL POPULATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOCOMPETENCE; IMMUNOTHERAPY; LEUKOCYTE COUNT; LIVER ABSCESS; LUNG ASPERGILLOSIS; MALE; MONOCYTE; OPEN STUDY; OSTEOMYELITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC MYCOSIS; TREATMENT DURATION; TREATMENT OUTCOME; CANDIDIASIS, INVASIVE; CLINICAL TRIAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS, INVASIVE; COMBINED MODALITY THERAPY; ECHINOCANDINS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 84897530707     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-166     Document Type: Article

References (60)

1. Segal BH, Steinbach WJ. Combination antifungals:an update. Expert Rev Anti Infect Ther 2007, 5(5):883-892. 10.1586/14787210.5.5.883, 17914921.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals:analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-317. 10.1086/421946, 15306996.
3. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37(9):1172-1177. 10.1086/378745, 14557960.
4. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Epidemiology and outcomes of candidemia in 2019 patients:data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48(12):1695-1703. 10.1086/599039, 19441981.
5. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States:a propensity analysis. Clin Infect Dis 2005, 41(9):1232-1239. 10.1086/496922, 16206095.
6. Warnock DW. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 2007, 48(1):1-12.
7. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers:human fungal infections. Sci Transl Med 2012, 4(165):165rv113.
8. Rodloff C, Koch D, Schaumann R. Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res 2011, 16(4):187-195. 10.1186/2047-783X-16-4-187, 3352075, 21486733.
9. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009, 15(7):1068-1076. 10.3201/eid1507.090043, 2744247, 19624922.
10. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol 2011, 3:175-191. 3130903, 21750627.
11. Romani L. Immunity to fungal infections. Nat Rev 2011, 11(4):275-288.
12. Cenci E, Mencacci A, Del Sero G, Bistoni F, Romani L. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J Infect Dis 1997, 176(1):217-226. 10.1086/514027, 9207370.
13. Netea MG, Vonk AG, van den Hoven M, Verschueren I, Joosten LA, van Krieken JH, van den Berg WB, Van der Meer JW, Kullberg BJ. Differential role of IL-18 and IL-12 in the host defense against disseminated Candida albicans infection. Eur J Immunol 2003, 33(12):3409-3417. 10.1002/eji.200323737, 14635050.
14. Chai LY, van de Veerdonk F, Marijnissen RJ, Cheng SC, Khoo AL, Hectors M, Lagrou K, Vonk AG, Maertens J, Joosten LA, Kullberg BJ, Netea MG. Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology 2010, 130(1):46-54. 10.1111/j.1365-2567.2009.03211.x, 2855792, 20002791.
15. Cenci E, Mencacci A, Del Sero G, Bacci A, Montagnoli C, d'Ostiani CF, Mosci P, Bachmann M, Bistoni F, Kopf M, Romani L. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999, 180(6):1957-1968. 10.1086/315142, 10558953.
16. Centeno-Lima S, Silveira H, Casimiro C, Aguiar P, do Rosario VE. Kinetics of cytokine expression in mice with invasive aspergillosis:lethal infection and protection. FEMS Immunol Med Microbiol 2002, 32(2):167-173. 10.1111/j.1574-695X.2002.tb00549.x, 11821239.
17. Ito JI. T cell immunity and vaccines against invasive fungal diseases. Immunol Invest 2011, 40(7-8):825-838.
18. Stuehler C, Khanna N, Bozza S, Zelante T, Moretti S, Kruhm M, Lurati S, Conrad B, Worschech E, Stevanovic S, Krappmann S, Einsele H, Latgé JP, Loeffler J, Romani L, Topp MS. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood 2011, 117(22):5881-5891. 10.1182/blood-2010-12-325084, 21441461.
19. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma:an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75(2):163-189.
20. Lehrnbecher T, Tramsen L, Koehl U, Schmidt S, Bochennek K, Klingebiel T. Immunotherapy against invasive fungal diseases in stem cell transplant recipients. Immunol Invest 2011, 40(7-8):839-852.
21. Stevens DA, Brummer E, Clemons KV. Interferon- gamma as an antifungal. J Infect Dis 2006, 194(Suppl 1):S33-S37.
22. Group TICGDCS A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991, 324(8):509-516. Group TICGDCS.
23. Riddell LA, Pinching AJ, Hill S, Ng TT, Arbe E, Lapham GP, Ash S, Hillman R, Tchamouroff S, Denning DW, Parkin JM. A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 2001, 17(9):789-797. 10.1089/088922201750251981, 11429120.
24. Bodasing N, Seaton RA, Shankland GS, Pithie A. Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient. J Antimicrob Chemother 2002, 50(5):765-766. 10.1093/jac/dkf206, 12407143.
25. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, Schutz C, Bekker LG, Wood R, Harrison TS. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis:a randomized controlled trial. Aids 2012, 26(9):1105-1113. 10.1097/QAD.0b013e3283536a93, 3640254, 22421244.
26. Poynton CH, Barnes RA, Rees J. Interferon gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin Infect Dis 1998, 26(1):239-240. 10.1086/517077, 9455573.
27. Dignani MC, Rex JH, Chan KW, Dow G, deMagalhaes-Silverman M, Maddox A, Walsh T, Anaissie E. Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer 2005, 104(1):199-204. 10.1002/cncr.21142, 15929126.
28. Armstrong-James D, Teo IA, Shrivastava S, Petrou MA, Taube D, Dorling A, Shaunak S. Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am J Transplant 2010, 10(8):1796-1803. 10.1111/j.1600-6143.2010.03094.x, 20353472.
29. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535. 10.1086/596757, 19191635, Infectious Diseases Society of America.
30. Oude Lashof AJ, Meis JFG, Warris A, van 't Wout JW, Natsch S, Van Zanten A, Verweij PE, Kullberg BJ, JJWM Optimalisation of the antibiotic policy in the Netherlands XIII. Dutch Working Party on Antibiotic Policy (SWAB) guideline for the treatment of invasive fungal infections. Nederlands tijdschrift voor geneeskunde 2009, 153:A901. JJWM.
31. Leentjens J, Kox M, Koch RM, Preijers F, Joosten LA, van der Hoeven JG, Netea MG, Pickkers P. Reversal of Immunoparalysis in Humans In Vivo:A Double-Blind, Placebo-controlled, Randomized Pilot Study. Am J Respir Crit Care Med 2012, 186(9):838-845. 10.1164/rccm.201204-0645OC, 22822024.
32. Netea MG, Warris A, Van der Meer JW, Fenton MJ, Verver-Janssen TJ, Jacobs LE, Andresen T, Verweij PE, Kullberg BJ. Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis 2003, 188(2):320-326. 10.1086/376456, 12854089.
33. van de Veerdonk FL, Marijnissen RJ, Kullberg BJ, Koenen HJ, Cheng SC, Joosten I, van den Berg WB, Williams DL, van der Meer JW, Joosten LA, Netea MG. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 2009, 5(4):329-340. 10.1016/j.chom.2009.02.006, 19380112.
34. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46(12):1813-1821. 10.1086/588660, 2671227, 18462102.
35. Eyerich S, Wagener J, Wenzel V, Scarponi C, Pennino D, Albanesi C, Schaller M, Behrendt H, Ring J, Schmidt-Weber CB, Cavani A, Mempel M, Traidl-Hoffmann C, Eyerich K. IL-22 and TNF-alpha represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur J Immunol 2011, 41(7):1894-1901. 10.1002/eji.201041197, 21469124.
36. Gresnigt MS, Netea MG, van de Veerdonk FL. Pattern recognition receptors and their role in invasive aspergillosis. Ann N Y Acad Sci 2012, 1273(1):60-67. 10.1111/j.1749-6632.2012.06759.x, 23230838.
37. Sainz J, Salas-Alvarado I, Lopez-Fernandez E, Olmedo C, Comino A, Garcia F, Blanco A, Gomez-Lopera S, Oyonarte S, Bueno P, Jurado M. TNFR1 mRNA expression level and TNFR1 gene polymorphisms are predictive markers for susceptibility to develop invasive pulmonary aspergillosis. Int J Immunopathol Pharmacol 2010, 23(2):423-436.
38. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001, 344(14):1099-1100.
39. Bellocchio S, Montagnoli C, Bozza S, Gaziano R, Rossi G, Mambula SS, Vecchi A, Mantovani A, Levitz SM, Romani L. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol 2004, 172(5):3059-3069.
40. Sainz J, Perez E, Gomez-Lopera S, Jurado M. IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. J Clin Immunol 2008, 28(5):473-485. 10.1007/s10875-008-9197-0, 18484169.
41. De Luca A, Zelante T, D'Angelo C, Zagarella S, Fallarino F, Spreca A, Iannitti RG, Bonifazi P, Renauld JC, Bistoni F, Puccetti P, Romani L. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol 2010, 3(4):361-373. 10.1038/mi.2010.22, 20445503.
42. Gessner MA, Werner JL, Lilly LM, Nelson MP, Metz AE, Dunaway CW, Chan YR, Ouyang W, Brown GD, Weaver CT, Steele C. Dectin-1-dependent interleukin-22 contributes to early innate lung defense against Aspergillus fumigatus. Infect Immun 2012, 80(1):410-417. 10.1128/IAI.05939-11, 3255669, 22038916.
43. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE, Spellberg B. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009, 5(12):e1000703. 10.1371/journal.ppat.1000703, 2792038, 20041174.
44. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452(7188):773-776. 10.1038/nature06764, 2864108, 18337720.
45. Smeekens SP, Henriet SS, Gresnigt MS, Joosten LA, Hermans PW, Netea MG, Warris A, van de Veerdonk FL. Low interleukin-17A production in response to fungal pathogens in patients with chronic granulomatous disease. J Interferon Cytokine Res 2012, 32(4):159-168. 10.1089/jir.2011.0046, 22191467.
46. Saulsbury FT. Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis 2001, 32(10):E137-E139. 10.1086/320158, 11317265.
47. Pasic S, Abinun M, Pistignjat B, Vlajic B, Rakic J, Sarjanovic L, Ostojic N. Aspergillus osteomyelitis in chronic granulomatous disease:treatment with recombinant gamma-interferon and itraconazole. Pediatr Infect Dis J 1996, 15(9):833-834. 10.1097/00006454-199609000-00021, 8878232.
48. Malmvall BE, Follin P. Successful interferon-gamma therapy in a chronic granulomatous disease (CGD) patient suffering from Staphylococcus aureus hepatic abscess and invasive Candida albicans infection. Scand J Infect Dis 1993, 25(1):61-66.
49. Ellis M, Watson R, McNabb A, Lukic ML, Nork M. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery. J Med Microbiol 2002, 51(1):70-75.
50. Kelleher P, Goodsall A, Mulgirigama A, Kunst H, Henderson DC, Wilson R, Newman-Taylor A, Levin M. Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J 2006, 27(6):1307-1310. 10.1183/09031936.06.00021705, 16772392.
51. Netea MG, Brouwer AE, Hoogendoorn EH, Van der Meer JW, Koolen M, Verweij PE, Kullberg BJ. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia:defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis 2004, 39(9):e83-e87. 10.1086/425121, 15494899.
52. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE, NIAID Mycoses Study Group A prospective observational study of candidemia:epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37(5):634-643. 10.1086/376906, 12942393, NIAID Mycoses Study Group.
53. Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P. Immunotherapy for the adjunctive treatment of sepsis:from immunosuppression to immunostimulation. Time for a paradigm change?. Am J Respir Crit Care Med 2013, 187(12):1287-1293. doi:10.1164/rccm.201301-0036CP, 10.1164/rccm.201301-0036CP, 23590272.
54. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients:restoration by IFN-gamma treatment. Nat Med 1997, 3(6):678-681. 10.1038/nm0697-678, 9176497.
55. Carson WF, Cavassani KA, Dou Y, Kunkel SL. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 2011, 6(3):273-283. 10.4161/epi.6.3.14017, 3092675, 21048427.
56. Armstrong-James D, Teo I, Herbst S, Petrou M, Shiu KY, McLean A, Taube D, Dorling A, Shaunak S. Renal allograft recipients fail to increase interferon-gamma during invasive fungal diseases. Am J Transplant 2012, 12(12):3437-3440. 10.1111/j.1600-6143.2012.04254.x, 22974244.
57. Turrel-Davin F, Venet F, Monnin C, Barbalat V, Cerrato E, Pachot A, Lepape A, Alberti-Segui C, Monneret G. mRNA-based approach to monitor recombinant gamma-interferon restoration of LPS-induced endotoxin tolerance. Crit Care 2011, 15(5):R252. 10.1186/cc10513, 3334803, 22027436.
58. Chen J, Ivashkiv LB. IFN-gamma abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling. Proc Natl Acad Sci U S A 2010, 107(45):19438-19443. 10.1073/pnas.1007816107, 2984206, 20974955.
59. Xiong Y, Medvedev AE. Induction of endotoxin tolerance in vivo inhibits activation of IRAK4 and increases negative regulators IRAK-M, SHIP-1, and A20. J Leukoc Biol 2011, 90(6):1141-1148. 10.1189/jlb.0611273, 3236548, 21934070.
60. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe:epidemiology and resistance. Int J Antimicrob Agents 2006, 27(5):359-366. 10.1016/j.ijantimicag.2006.01.002, 16647248.